tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
Company AnnouncementsPharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
6d ago
6K
PHVS
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
PremiumRatings
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
8d ago
PHVS
Pharvaris price target raised to $46 from $41 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $46 from $41 at Morgan Stanley
8d ago
PHVS
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
PremiumRatings
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
21d ago
PHVS
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
PremiumCompany Announcements
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
22d ago
6K
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe FlyPharvaris management to meet with Oppenheimer
29d ago
PHVS
Pharvaris management to meet with Oppenheimer
Premium
The Fly
Pharvaris management to meet with Oppenheimer
1M ago
PHVS
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
Premium
Ratings
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
1M ago
PHVS
Pharvaris price target raised to $33 from $31 at BofA
PremiumThe Fly
Pharvaris price target raised to $33 from $31 at BofA
2M ago
PHVS
Pharvaris price target lowered to $74 from $75 at Citizens
PremiumThe Fly
Pharvaris price target lowered to $74 from $75 at Citizens
2M ago
PHVS
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
PremiumThe Fly
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
2M ago
PHVS
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
PremiumCompany Announcements
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
2M ago
6K
PHVS
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
PremiumCompany AnnouncementsPharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
2M ago
6K
PHVS
Pharvaris price target raised to $31 from $30 at BofA
Premium
The Fly
Pharvaris price target raised to $31 from $30 at BofA
2M ago
PHVS
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
Premium
Ratings
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
2M ago
PHVS
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
PremiumThe Fly
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
2M ago
PHVS
Pharvaris price target raised to $52 from $48 at JonesResearch
PremiumThe Fly
Pharvaris price target raised to $52 from $48 at JonesResearch
3M ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
PremiumRatings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
3M ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
3M ago
ANET
BCRX
Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
PremiumThe FlyTexas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
3M ago
KR
ZS
Pharvaris initiated with an Outperform at Wolfe Research
Premium
The Fly
Pharvaris initiated with an Outperform at Wolfe Research
3M ago
PHVS
Pharvaris price target raised to $42 from $41 at Wedbush
Premium
The Fly
Pharvaris price target raised to $42 from $41 at Wedbush
3M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >